FDA REFORM DEBATE MAY SPUR "MORE INFORMED" OVERSIGHT OF FDA BY CONGRESS, SENATE STAFFER SAYS; PDUFA REAUTHORIZATION SETS 5-YEAR CYCLE FOR FD&C ACT REVIEW